Fosciclopirox disodium suppresses urothelial cancer growth by targeting the γ-secretase complex and selectively delivering the active metabolite, Ciclopirox, throughout the urinary tract. Ciclopirox demonstrates anticancer activity in various solid and hematologic malignancies [1] [2].